Purpose: β Cell specificity for a heterobivalent ligand composed of glucagon-like peptide-1 (GLP-1) linked to yohimbine (GLP-1/Yhb) was evaluated to determine its utility as a noninvasive imaging agent. Procedures: Competition binding assays were performed on βTC3 cells and isolated rat islets. Immunostaining for insulin was used to co-localized intravenously injected Cy5-labeled GLP-1/ Yhb in β cells of Sprague-Dawley rats. Rats were intravenously injected with In-111-labeled GLP-1/Yhb to determine clearance rates and tissue biodistribution. Tissue-specific binding was confirmed by competition with pre-administration of unlabeled GLP-1/Yhb and in Streptozotocininduced diabetic rats. Results: In βTC3 cells, high affinity binding of GLP-1/Yhb required interactions with both receptors because monovalent competition or receptor knockdown with RNAi lowered specificity and avidity of the heterobivalent ligand. Binding specificity for isolated islets was 2.6-fold greater than that of acinar tissue or islets pre-incubated with excess unlabeled GLP-1/Yhb. Immunofluorescent localization of Cy5-labeled GLP-1/Yhb was restricted to pancreatic islets. Within 30 min,~90 % of the In-111-labeled GLP-1/Yhb was cleared from blood. Tissue-specific accumulation of radiolabeled ligand was apparent in the pancreas, but not in other tissues within the abdominal imaging field. Pancreas specificity was lost in Streptozotocin-induced diabetic rats. Conclusions: The GLP-1/Yhb exhibits high specificity for β cells, rapid blood clearance rates, and low non-specific uptake by other tissues within the abdominal imaging field. These characteristics of GLP-1/Yhb are desirable for application to β cell imaging in vivo and provide a basis for developing additional multivalent β cell-specific targeting agents to aid in the management of type 1 diabetes.
Introduction

L
oss of insulin secretion due to destruction of pancreatic β cells is a distinguishing feature in patients with type 1 diabetes mellitus. To evaluate the progression of β cell loss prior to diabetes and to monitor the efficacy of therapeutic strategies to retard β cell destruction in pre-diabetic patients, a non-invasive measure of β cell mass is required. Imaging agents for β cells have been identified and contrast agents linked to single ligands or antibodies have been used to evaluate β cell mass [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . For example, attempts to measure β cell mass in vivo with agonists for the glucagonlike peptide 1 receptor (GLP-1R) have shown promise [9, 12, 13] . However, additional benefits exist for improved probe selectivity and avidity. These benefits include a greater dynamic range for detection [3, 5] .
We propose that β cell imaging agents can be improved to meet the needed requirements by using the concept of multivalency. Multivalent ligands are composed of multiple binding domains tethered together by flexible linkers that allow each binding domain to simultaneously access their complementary receptors on a cell's surface. We previously demonstrated that multivalent ligands exhibit enhanced apparent affinity, to cells expressing the complementary receptor pair, when compared to their constituent monovalent molecules [14] [15] [16] . For example, a homomultivalent melanocyte-stimulating hormone based ligand (two of the same moiety tethered together) bound with higher apparent affinity compared to the monovalent ligand [17, 18] . This enhanced affinity requires an ability of each binding domain within the ligand to access its receptors either simultaneously or within a limited time frame [19] . In this respect, a heteromultivalent ligand (two or more different moieties) exhibited a higher apparent binding affinity to cells expressing both receptors compared to cells that expressed only one of the complementary pair, demonstrating cell-type specificity [16] .
In this study, we describe the synthesis and testing of a multivalent ligand composed of GLP-1 and a α2 adrenergic receptor antagonist, yohimbine (Yhb). Glucagon-like peptide-1 receptor is abundantly expressed in rodent and human pancreatic β cells making it a suitable target for noninvasive monitoring of β cell mass [20] [21] [22] [23] [24] . In vivo and in vitro imaging approaches for GLP-1R agonists demonstrate it has a β cell targeting capabilities [2, 9, 25, 26, 27] . Depending on the extent to which uptake in non-target tissues are related to clearance mechanisms, approaches that enhance GLP-1 avidity and specificity may increase specific uptake of the radiotracer which could result in increased signal-to-noise. Therefore, approaches to enhance GLP-1 avidity and specificity would be advantageous. Alpha-2 adrenergic receptors (Adrα2) also are present on human and rodent β cells and provide a class of G-protein coupled receptors with several well characterized and approved pharmaceutical agents [22, [28] [29] [30] . The aim of this study was to evaluate the ability of the GLP-1/Yhb construct to target specifically to β cells and thereby evaluate its potential as a noninvasive imaging agent.
Materials and Methods
Ligand Synthesis
Heterobivalent DTPA-GLP-1/Yhb and Cy5-GLP-1/Yhb were synthesized using standard Fmoc/tBu chemistry (summarized in Fig. 1 ) on Rink Amide Tentagel resin (0.23 mmol/g) [16, 31] . The resulting compounds were fully de-protected and cleaved from the resin by treatment with 91 % trifluoroacetic acid (TFA) (3 % water, 3 % 1, 2-ethanedithiol, and 3 % thioanisole). After ether extraction of scavengers, compounds were purified by high-performance liquid chromatography (HPLC) and/or size-exclusion chromatography (Sephadex G-25, 0.1 M acetic acid) to 995 % purity. All compounds were analyzed for purity by analytical HPLC and mass spectrometry (MS). 
Ligand Radiolabeling
The DTPA-GLP-1/Yhb ligand was purified with preparative HPLC and lyophilized. The dry ligand was dissolved in 20 % acetonitrile/ 0.5 M ammonium acetate (1 mg/ml) and 1. 
Cell Culture and shRNA Transfection
SureSilencing™ shRNA plasmids containing GFP were purchased for GLP-1R and Adrα2A (Qiagen Inc., Valencia, CA, USA). Control and gene-specific shRNA plasmids for each receptor were amplified in Mach1 E. Coli cells (Invitrogen Life Techonology, Grand Island, NY, USA) and purified with a Qiagen Plasmid Midi Kit. The control plasmid expresses a shRNA sequence that does not match anything in the relevant genome. βTC3 cells were cultured under standard conditions (humidified incubator at 37°C with 5 % CO 2 ) in RPMI media supplemented with 10 % FBS and 1 % Penicillin/Streptomycin. Cells were plated in six-well plates and cultured for 24 h prior to transfection. βTC3 cells were transfected using Lipofectamine 2000 and shRNA plasmid (4 μg/well) complexes according to manufacturer's instructions. Transfection efficiency was determined by fluorescence detection of GFP. The duration post transfection was optimized to achieve maximum receptor knock-down of protein concentrations.
Western Blotting
Polyacrylamide gel electrophoresis and immunoblotting was performed on 50 μg of βTC3 protein as described previously [32] . The primary antibodies for immunoblotting were raised in rabbit against GLP-1R, Adrα2A and β-tubulin (1:500; Santa Cruz Biotechnologies, Santa Cruz, CA, USA) and detected with Super Signal West Pico chemiluminescent reagent (Pierce, Rockford, IL). The membranes were exposed to x-ray film and densitometry measured with ImageJ image analysis software (National Institute of Mental Health, Bethesda, Maryland, USA).
βTC3 Receptor Binding Specificity βTC3 cells were incubated with designated concentrations of Cy5-labeled GLP-1/Yhb with and without unlabeled competitors (1 μM GLP-1 or 1 μM Yhb) for 2 min, then the media was replaced with ligand-free buffer. All images for Cy5-labeled GLP-1/Yhb binding were acquired 3 min after buffer replacement. This time point was chosen because previous experiments indicated that binding was complete, but removal from at or near the cell surface was minimum. On average, groups of 10-20 cells were imaged for each coverslip. A region of interest (ROI) was drawn at the cell membrane to obtain the average pixel intensity within that region 4 , and 5.6 mM glucose). Receptor binding was measured with the Cy5-labeled GLP-1/Yhb ligand. Cy5 fluorescence was excited using a 100-W Hg lamp as the excitation source with the white light passed through a 60-nm band pass filter centered at 620 nm. The emitted light was appropriately filtered at 700 nm using a 75-nm band pass prior to focusing the cell image onto a Photometrics Cascade 512B camera. Cy5 was chosen because background auto-fluorescence at these wavelengths was minimal, and therefore optimal for observing binding at low fluorophore/ligand concentrations.
For the knockdown experiments, βTC3 cells were imaged first for GFP fluorescence to distinguish transfected (GFP positive) from non-transfected (GFP negative) cells then the filter was switched to the Cy5 filter set. Image acquisition and analysis for Cy5-labeled GLP-1/Yhb binding was identical to that described above.
Binding Specificity for Isolated Rat Islets
Islets were isolated using the collagenase (Sigma Type V) technique as described previously [33] . Eight isolations were performed in total with islets pooled from two rats per isolation. Rat islets were hand-picked under a microscope and cultured overnight in CMRL supplemented media (10 % FBS, 1× Pen-Strep, and 11 mM glucose) in an oxygen chamber supplemented with 95 % O 2 and 5 % CO 2 in a humidified incubator at 37°C. Partially digested acinar clusters were also cultured overnight under the same conditions. Eight binding experiments were carried out with 50 islets or acinar clusters (100 μl CMRL media) in 100 μl of HBSS media supplemented with 0.5 % BSA (n=2 replicates/ tissue type for each isolation/experiment). Half of the islet and acinar replicates were pre-incubated for 5 min with unlabeled GLP-1/Yhb ligand (2,540 nmoles/l) to determine specific binding of the In-111-labeled GLP-1/Yhb ligand. The In-111-labeled GLP-1/Yhb ligand (10.98±1.47 nmoles/l in 50 μl of saline with 0.5 % BSA) was added to all replicates and incubated at 37°C for 5 min. Media were removed and tissues were washed in ice-cold, serum-free DMEM media five times. Tissues were homogenized in RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 2 mM EDTA, pH 8.0, 50 mM NaF, 1 % Triton X-100, 1 % Deoxycholic Acid, 0.1 % SDS, 1 mM DTT). Homogenized samples were used to determine radioactivity and protein concentrations (Pierce Microplate BCA Protein Assay Kit from Thermo Scientific, Rockford, IL, USA). Results are presented as disintegrations per minute (DPM) per protein content (DPM/ug of protein).
In vivo Specificity of Cy5-Labeled GLP-1/Yhb in the Rat
Six anesthetized rats were injected with 5 nmoles of Cy5-labeled GLP-1/Yhb ligand via the saphenous vein to achieve an estimated blood concentration of 250 nmoles/l. Optimal estimated blood concentrations were previously determined with a dose response study (data not shown). Thirty minutes after ligand administration, rats were euthanized and pancreas was collected. Pancreas was also collected from control (non-injected) rats to identify background intensity. Pancreas tissue was fixed in 4 % paraformaldehyde (PFA) in phosphate buffered saline (PBS) and embedded in optimal cutting temperature (OCT) compound (Tissue Tek manufactured for Sakura Finetek Inc, Torrance, CA, USA). Pancreatic sections (6 μm) were immunostained for insulin (guinea pig anti-porcine insulin; 1:500, Dako, Carpinteria, CA, USA) and detected with affinity-purified secondary antiserum conjugated to aminomethylcoumarin acetate (AMCA, Jackson ImmunoResearch Laboratories, West Grove, PA, USA) as previously described [34] . Independent images for each fluorophore were acquired using a Leica DM5500 Microscope System equipped with an A4 (insulin, ExCitation Filter BP360/40, Dichromatic mirror 400, and Suppression Filter BP 470/40) and Y5 (Cy5, ExCitation Filter BP 620/60, Dichromatic mirror 660, and Suppression Filter BP 700/75) filter cubes and a Leica EL600 compact light source with a HXP-R120W/45C VIS lamp as an excitation source. Images were digitally captured with 208-msec exposure for insulin and 10,353-msec exposure for Cy5 using a Spot Pursuit 4 Megapixel CCD camera (Diagnostic Instruments, Inc., Sterling Heights, MI, USA). Intensities for five islets and acinar tissue images were measured on 20 pancreas sections from each rat using Image Pro Plus 6.3 software (Media Cybernetics, Silver Spring, MD, USA), and the ratio of islet to acinar tissue intensities were calculated for each section then averaged for all sections.
Experimental Animals
Male Sprague-Dawley rats weighing 300 g at 8-9 weeks of age were purchased from Harlan (Livermore, CA, USA). Four rats received one intraperitoneal injection of Streptozotocin (60 mg/kg; Sigma-Aldrich, St. Louis, MO, USA) reconstituted using 0.1 M sodium citrate buffer (pH 4.5). Blood glucose concentrations were measured daily using a True Track Glucose Monitoring System (NIPRO Diagnostics, Fort Lauderdale, FL, USA). Rats were considered diabetic when their blood glucose concentrations exceeded 200 mg/dl. All rats exhibited blood glucose concentrations 9200 mg/dl for three consecutive days prior to the start of the experiment. All experiments were performed with the approval of and in accordance with guidelines established by the Institutional Animal Care and Use Committee at The University of Arizona.
Blood Clearance Rate and Biodistribution
Rats were anesthetized with Ketamine and Xylazine and intravenously injected via the saphenous vein with the In-111-labeled GLP-1/Yhb ligand (0.53±0.06 nmoles in 1 ml of sterile saline). Four rats received 20 nmoles of unlabeled GLP-1/Yhb ligand in 0.5 ml of saline 10 min prior to administration of radiolabeled ligand and were compared to seven rats that received radiolabeled ligand only. Blood samples were collected from the tail vein at 0, 1, 3, 5, 10, 20, 30, and 45 min following In-111-labeled GLP-1/Yhb administration. After the 45-min blood sample was collected, the rats were euthanized, dissected, and organs were collected. The organs and tissues were rinsed in saline three times, blotted dry, and weighed. Five samples (~2 mm 
Analysis of Pancreatic β Cell Mass in Streptozotocin-Induced Diabetic Rats
Following the experiment, rats were euthanized and pancreas was collected. Pancreas tissue was fixed in 4 % PFA in PBS and embedded in OCT. Pancreatic sections (6 μm) were immunostained for insulin, somatostatin (rabbit anti-bovine somatostatin; 1:500, DakoCarpinteria, CA, USA), and glucagon (mouse anti-porcine glucagon; 1:250, Sigma-Aldrich, St. Louis, MO, USA) and detected with affinity-purified secondary antiserum conjugated to AMCA, Dylight 594, and Alexa 488, respectively (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) as previously described [34] . Beta cell mass for each animal was obtained as described previously [34] [35] [36] .
Statistical Analysis
Fluorescence intensities for competitive binding experiments were analyzed within a concentration by a least squares analysis of variance . Previously, we reported that on average 250,000-300,000 GLP-1R are expressed per βTC3 cell (passage 46-47), using a high-throughput screening assay [14] . This is at least 2-fold higher than the number of Adrα2A receptors expressed on these βTC3 cells. Therefore the magnitude of bivalent binding (below 50 nM) is limited by the number of Adrα2A. Conversely, the high level of binding of the GLP-1 element within the GLP-1/Yhb, at 50 nM and above (in the presence of cold Yhb), is due to binding to available "spare" GLP-1R [14] . The requirement of both complementary receptors for binding below 50 nM was evaluated by reducing receptor expression with shRNA. GLP-1R or Adrα2A protein concentrations were decreased with transient transfections of shRNA plasmids in βTC3 cells (Fig. 3) . GLP-1R was reduced by 82-96 % and Adrα2A was reduced by 93-97 % at 72 h post transfection.
Binding of Cy5-labeled GLP-1/Yhb to cells transiently transfected with receptor specific shRNA plasmid was (Fig. 4) . In addition to 25 nM Cy5-GLP-1/Yhb, less binding was seen on cells with knockdown of either GLP-1R (Fig. 4c) or α2AR (Fig. 4d) compared to substantial binding (~2-fold greater intensity) in non-transfected cells within the same field of view. The average fluorescent intensity of βTC3 cells that bound Cy5-labeled GLP-1/Yhb and were transfected with GLP-1R or Adrα2A shRNA plasmids was 43.1 or 45.3 % less, respectively, than the non-transfected cells expressing both receptors. Together, these data demonstrate that at low concentrations (G50 nM), GLP-1/Yhb binds preferentially to cells when both of its cognate receptors are accessible for binding relative to cells where only one receptor is accessible on the cell surface.
Isolated Islet Sequestration of In-111-Labeled GLP-1/Yhb
In isolated islets incubated with In-111-labeled GLP-1/Yhb, accumulation was 2.6-fold greater (PG0.05) than that of islets incubated with In-111-labeled GLP-1/Yhb in the presence of 230-fold greater unlabeled GLP-1/Yhb (Fig. 5) . In contrast, specific binding was not observed in acinar tissue because unlabeled competitor was ineffective. Furthermore, islets incubated with only In-111-labeled GLP-1/Yhb had accumulation greater than (PG0.05) both acinar tissue treatment groups.
Pancreatic Cellular Specificity of Cy5-Labeled GLP-1/Yhb
After an intravenous injection, Cy5-labeled GLP-1/Yhb colocalized with β cells that were immunostained with insulin (Fig. 6) . Fluorescence intensities for Cy5 were compared as ratios for insulin-positive areas to surrounding pancreas tissue (Fig. 6) . The average intensity ratio for sections acquired from non-injected rats was not different than 1, indicating that background in the Cy5 filter was homogeneous for β cell and acinar tissues. The β cell to acinar fluorescence intensity ratio was 1.8-fold in rats injected with Cy5-labeled GLP-1/Yhb, which was greater (PG0.01) than non-injected rats.
Biodistribution of In-111-Labeled GLP-1/Yhb
In circulation, maximum blood concentrations of In-111-labeled GLP-1/Yhb were observed 1 min (338.1±3.4 nmoles/ L) post intravenous injection (Fig. 7) . The rate of clearance of , where x is time in minutes and y is radioactivity in DPMs. Less than 13 % (44.89±6.78 nM) of the In-111-labeled GLP-1/Yhb was present in circulation 45 min after injection.
Organs were collected 45 min following injection, a time after which blood activity was 0.70±0.53 %IA/g of tissue.
Tissue distribution analysis for theIn-111-labeled GLP-1/ Yhb showed that the kidneys accumulated the greatest proportion of the injected activity (16.24±1.45 %IA/g of tissue; Table 1 ). The lungs acquired the second highest proportion of In-111 activity at 1.38±0.43 %IA/g of tissue, while the pancreas proportion of 111 In activity was 0.18± 0.07 %IA/g of tissue, with all other tissues retaining less than 1.0 %IA/g of tissue 45 min after injection.
Specific binding of In-111-labeled GLP-1/Yhb within each tissue was determined by pre-injection of saturating unlabeled GLP-1/Yhb (Table 1) . Tissue-specific accumulation for the radiolabeled ligand was apparent only in the pancreas (PG0.05) and lung (PG0.05). No differences were observed in other tissues between In-111-labeled GLP-1/ Yhb and unlabeled GLP-1/Yhb.
Biodistribution of In-111-Labeled GLP-1/Yhb in Streptozotocin-Induced Diabetic Rats
Streptozotocin-induced diabetic rats were used to evaluate pancreas specificity for In-111-labeled GLP-1/Yhb. Blood clearance kinetics in the β cell-depleted rats was similar to those non-diabetic rats (Fig. 7) . Biodistribution also was similar in control and diabetic rats, except that the specific binding in the pancreas was lost (Table 1) .
In-111-labeled GLP-1/Yhb in the pancreas was similar to that observed for pancreata obtained from rats injected with unlabeled GLP-1/Yhb prior to receiving the In-111-labeled GLP-1/Yhb (Table 1 ). Both groups of rats have lower (PG0.05) pancreas binding compared to control rats injected only with In-111-labeled GLP-1/Yhb. Streptozotocin-induced β cell demise in diabetic rats was confirmed by immuno-fluorescent analysis for insulinpositive area. Streptozotocin-induced diabetic rats had 0.17 ± 0.01 % β cell-positive area, which was less (PG0.01) than the 1.93±0.01 % β cell-positive area found in normal, control rat pancreas. The pancreata from Streptozotocin-induced diabetic rats had similar α-celland δ-cell areas as controls.
Discussion
Prerequisite for non-invasive β cell imaging agents requires that probes have high specificity and avidity for β cells and be readily cleared from circulation to reduce background in adjacent tissues due to the relatively small size of β cell mass. In this study, a newly synthesized heterobivalent ligand composed of GLP-1 and yohimbine was evaluated, and for the first time we demonstrate the capability of a multivalent synthetic molecule to bind to an insulinoma cell line and untransformed β cells. Binding experiments with the βTC3 cells demonstrate that access to both cognate receptors is required for high affinity GLP-1/Yhb. Moreover, in vivo experiments demonstrate that, within the pancreas and abdominal tissues, GLP-1/Yhb binding was specific for β cells, which was further confirmed by loss of specific binding in pancreata of Streptozotocin-induced diabetic rats and in isolated rat islets.
An important characteristic of these multivalent ligands is their relatively small molecular weight which should provide kinetic properties required of an imaging agent. The washout to steady state of In-111-labeled GLP-1/Yhb occurred within 30 min of injection confirming this advantage. In order to evaluate the level of binding of In-111-labeled GLP-1/Yhb to islets, an estimate of β cell mass was determined using a paired cohort of rats (age and weight matched) from the same delivery as the rats that received the In-111-labeled GLP-1/Yhb injection. The approximate β cell mass was 2 % of the pancreas mass in control rats, using the approach described in the methods to measure β cell mass in the Streptozotocininduced diabetic rats. To determine β cell specific binding within the pancreas, %IA/g of tissue for Streptozotocininduced diabetic rats was subtracted from the %IA/g of tissue for the In-111-labeled GLP-1/Yhb injected rats. The β cell deficient, diabetic rats account for all non-β cell binding within the pancreas. Using this calculation, In-111-labeled GLP-1/ Yhb binding activity was 7.45±1.15 %IA/g of tissue, which was greater (PG0.05) than the level found in rats injected with unlabeled GLP-1/Yhb plus In-111-labeled GLP-1/Yhb (0.0± 0.1 %IA/g of tissue). These findings demonstrate the utility for multivalent constructs with low retention times in circulation to bind with high specificity to native pancreatic β cells. Furthermore, the flexibility in synthesis of the multivalent construct suggests potential to further refine β cell targeting agents by using either additional β cell ligands or other novel ligand combinations.
A range of β cell active agents were previously evaluated and shown to have sub-optimal binding specificity and sensitivity for in vivo imaging [5] . The β cell-specific monoclonal antibodies, K14D10 and IC2, were evaluated in vivo, but exhibited slow clearance rates from circulation and accumulated in the liver [3] . Although not exclusively expressed in the β cell, ligands with high specificity for β cells also have been tested, including glibenclamide deriva t i v e s ( s u l f o n y l u r e a r e c e p t o r 1 ; S U R 1 ) [ 3 7 ] , dihydrotetrabenazine (vesicular monoamine transporter type 2; VMAT2) [38] , and naphthylalanin derivatives (somatostatin receptor) [39] . These ligands demonstrated pancreatic binding, but accurate assessment or visualization of β cell mass in vivo was limited by non-specific binding [5, 37, 39] . One family of ligands that show promise for β cell targeting are modulators of the GLP-1 receptor, which has been evaluated for noninvasive monitoring of β cell mass and tumor detection, because of its robust expression in β cells compared to surrounding pancreatic tissue [2, 9-13, 25, 40, 41] . Here, we expand on GLP-1 as a targeting agent, and show GLP-1/Yhb biodistribution is restricted to the lung and pancreas. Moreover, specificity for pancreatic β cells is improved with bivalent binding of GLP-1/Yhb compared to monovalent GLP-1R (Figs. 2 and 4) .
The specificity and avidity of the GLP-1/Yhb construct is greater than the individual binding characteristics due to the requirement of simultaneous interaction of the two independent binding domains (GLP-1, Yhb) to their complementary receptors (Figs. 2 and 4) [19] . Furthermore, the innate affinity of the GLP-1 binding domain within the construct for the GLP-1 receptor is predicted to be decreased (Fig. 3) [14] , due to steric hindrance caused by the linker and second binding domain [14, 15] , which would subsequently lower binding to tissues expressing the GLP-1R alone. Regardless, the overall avidity of the ligand is improved by the second moiety, in this case Yhb, eliciting greater specificity. This finding is consistent with previous studies showing enhanced specificity of a melanocytestimulating hormone (MSH)/(CCK) bivalent construct for transformed cell lines expressing Human Melanocortin-4 (MSH) and Cholecystokinin-2 (CCK) receptors [15, 16, 42] . Improving current targeting agents will increase the prospects for noninvasive β cell imaging for clinical evaluation of β cell mass. Although some ligands for single receptors or molecules show promise, we demonstrate that synthetic heterobivalent ligands, such as GLP-1/Yhb, can be developed to increase cellular specificity and sensitivity while maintaining low retention times in circulation [14, 15] . These qualities meet necessary criteria for a successful imaging agent, low retention and increased β cell sensitivity. Moreover, we show that GLP-1/Yhb exhibits high specificity for native β cells and low non-specific uptake into other organs within the abdominal field. This experimental design provides a basis for developing additional β cells-specific imaging agents by using other ligand combinations or additional binding domains [17] .
